Palbociclib
- Generic Name
- Palbociclib
- Brand Names
- Ibrance
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N7O2
- CAS Number
- 571190-30-2
- Unique Ingredient Identifier
- G9ZF61LE7G
- Background
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
...
- Indication
Palbociclib is indicated in combination with letrozole as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with fulvestrant in patients with disease progress...
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Scorpion Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05768139
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇮🇹Fondazione Policlinico Universitario A Gemelli-Rome, Roma, Lazio, Italy
🇮🇹Istituto Europeo di Oncologia, Milano, Lombardia, Italy
A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
- Conditions
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05766410
- Locations
- 🇨🇳
Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan
🇨🇳Department of Oncology,National Taiwan University Hospital, Taipei, Taiwan
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Relay Therapeutics, Inc.
- Target Recruit Count
- 265
- Registration Number
- NCT05759949
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Community Cancer Center North, Indianapolis, Indiana, United States
🇺🇸Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05725200
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma
- Conditions
- Interventions
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 77
- Registration Number
- NCT05694871
- Locations
- 🇺🇸
UH Seidman Cancer Center at UH Avon Health Center, Avon, Ohio, United States
🇺🇸Creighton University Medical Center, Omaha, Nebraska, United States
🇺🇸Fresno Cancer Center, Fresno, California, United States
Palbociclib or Tazemetostat in Combination With CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 24
- Registration Number
- NCT05627232
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05563220
- Locations
- 🇩🇪
Universitaetsklinikum Mannheim, Mannheim, Baden-Wuerttemberg, Germany
🇺🇸Dothan Hematology and Oncology, Dothan, Alabama, United States
🇺🇸Mayo Clinic - Arizona, Phoenix, Arizona, United States
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Conditions
- Metastatic HER2-Negative Breast CarcinomaLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Malignant Female Reproductive System NeoplasmRecurrent Ovarian CarcinomaUnresectable HER2-Negative Breast CarcinomaUnresectable Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
- Interventions
- Procedure: BiopsyDrug: AlpelisibDrug: BinimetinibProcedure: Bone Marrow AspirationProcedure: Biospecimen CollectionProcedure: Bone ScanDrug: IpatasertibProcedure: Computed TomographyProcedure: EchocardiographyDrug: Nilotinib Hydrochloride MonohydrateBiological: PanitumumabProcedure: Magnetic Resonance ImagingDrug: PaclitaxelDrug: SotorasibDrug: OlaparibDrug: FluorouracilProcedure: Mutation Carrier ScreeningDrug: Neratinib MaleateDrug: LeucovorinDrug: FulvestrantProcedure: Positron Emission TomographyDrug: PalbociclibProcedure: Multigated Acquisition ScanDrug: Selumetinib SulfateDrug: Oxaliplatin
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2900
- Registration Number
- NCT05564377
- Locations
- 🇺🇸
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea, Michigan, United States
🇺🇸Corewell Health Dearborn Hospital, Dearborn, Michigan, United States
🇺🇸Corewell Health Farmington Hills Hospital, Farmington Hills, Michigan, United States
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
- Conditions
- Interventions
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 199
- Registration Number
- NCT05554367
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸UCHealth University of Colorado Hospital, Aurora, Colorado, United States
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
- Conditions
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Celcuity Inc
- Target Recruit Count
- 701
- Registration Number
- NCT05501886
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸Bond & Steele Clinic, P.A. d/b/a Bond Clinic, P.A., Winter Haven, Florida, United States
🇺🇸John D. Archbold Memorial Hospital, Thomasville, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.